Background. Frequency of enterococcal bloodstream infection (E-BSI) is increasing, and the number of episodes complicated by infective endocarditis (IE) varies. Performing transesophageal echocardiography (TEE) in all patients with E-BSI is costly and time-consuming. Our objectives were to identify patients with E-BSI who are at very low risk of enterococcal IE (and therefore do not require TEE) and to compare the outcome of E-BSI in patients with/without IE.
Enterococcus species is an increasingly common cause of bloodstream infections (E-BSI) in many institutions. The percentage of patients with E-BSI who have infective endocarditis (IE) is estimated to be between 3% and 10% [1] [2] [3] . The difference in these values is partially due to the study population selected and the methods used to confirm endocarditis. Some authors analyzed all patients with E-BSI [4] [5] [6] , whereas others only included patients with at least 2 positive blood cultures [2, [7] [8] [9] .
Establishing a diagnosis of enterococcal IE frequently requires transesophageal echocardiography (TEE) [10, 11] . However, use of TEE in all patients with E-BSI is costly, time consuming, and subject to complications.
Here, our objectives were to identify factors that enable early selection of a subgroup of patients with E-BSI who are at very low risk for enterococcal IE and in whom TEE could be avoided. We also compared the outcome of E-BSI in patients with and without IE in order to assess the potential consequences of misdiagnosis.
MATERIALS AND METHODS
Our design included 2 studies. In the first one, we aimed to assess the frequency of enterococcal IE by analyzing a prospective cohort that included all patients with E-BSI. In the second, we performed a case-control study and compared patients with and without enterococcal IE. Both studies were performed in a 1550-bed tertiary center attending a population of 715 000.
Prospective Cohort Study
The study sample comprised all cases of E-BSI diagnosed in our institution from September 2003 to October 2012. During this period, we identified 2 phases that differed with respect to the diagnosis of IE. From 2003 to 2007, patients with E-BSI were managed by the attending physician who requested consultation with the infectious diseases department or the laboratory of echocardiography [3] according to his/her own criteria ( period A). From 2008 to 2012 ( period B), a physician from the infectious diseases department visited the patients with E-BSI and promoted the systematic use of echocardiography. We recommended the systematic performance of TEE in most patients, provided the patient consented to and the attending physician agreed with the indication. Occasionally, the cardiologist indicated the need for TEE in patients referred for transthoracic echocardiography (TTE). Accordingly, in some patients, only TTE was performed, in some TTE and TEE, and in others neither of the 2 techniques was performed. From September 2003 onward, clinical data on all patients with enterococcal IE were collected prospectively as part of a preestablished protocol.
Case-Control Study
We designed a case-control study to identify a subgroup of patients at very low risk of enterococcal IE in whom systematic TEE could safely be deemed unnecessary. All patients fulfilling the modified Duke criteria [12] for IE were considered cases, and patients with E-BSI and a TEE result that ruled out IE were considered controls. Control patients were randomly selected from among patients with E-BSI and a negative TEE result and no criteria for IE according to the modified Duke criteria [12] . Both groups were independently selected from the period in which they presented.
To evaluate the possibility of misdiagnosed IE, we reviewed the clinical records of a randomly selected significant sample (176/1127) of patients with enterococcal bacteremia who did not undergo TEE. We analyzed primary clinical characteristics and duration of therapy. The selected parameters were previous valve disease; origin of bacteremia; number of positive blood cultures; recurrence of bacteremia; clinical, microbiological, and/or radiological findings suggestive of septic embolism; NOVA score (Number of positive blood cultures, Origin of the bacteremia, previous Valve disease, Auscultation of heart murmur); and treatment and outcome during admission and follow-up. Patients were followed up for a mean of 653 days after discharge.
Definitions and Evaluation Criteria
We used the following definitions:
Blood culture was defined as a volume of blood obtained under aseptic conditions and inoculated into 2 bottles for microbiologic isolation [8] .
BSI episode, episode of bacteremia, refers only to patients, not to number of blood cultures. All microorganisms isolated from blood from the same patient within 1 week were considered a single episode [8] .
Continuous bacteremia is a positive result in all of 3 blood cultures, or the majority if more than 3 blood cultures (with the first and last sample drawn at least 1 hour apart) [13] .
Infective endocarditis was diagnosed according to the modified Duke criteria [12] . Patients with IE were followed for 1 year after discharge.
Underlying diseases were classified according to the McCabe and Jackson scale [14] . Comorbidities were assessed using the Charlson comorbidity score [15] .
Ethical Issues
The Institutional Review Board and Ethics Committee of Hospital Gregorio Marañón, Madrid, Spain, approved the study (EC 106/13).
Statistical Analysis
In the descriptive study, qualitative variables are presented as percentages with their confidence interval (CI) and quantitative variables are presented as the mean and CI and/or median with the interquartile range, depending on the distribution. Clinical and microbiological variables were studied to obtain a predictive model for enterococcal endocarditis. Differences between groups were analyzed using the t test, median test, χ 2 test, or Fisher exact test, depending on the characteristics of the variables and their distribution between groups. The sensitivities of TTE and TEE were compared using a McNemar test for pair samples. The evolution of the variables during the study period was assessed using the autoregressive integrated moving average test. In order to develop a reliable algorithm that made it possible to rule out the need for TEE, we designed a strategy based on bootstrapping. Given that the same case-control dataset was used for developing the model, testing, assessing goodness of fit, and establishing threshold values, we implemented bootstrapping techniques to avoid overfitting. The association between individual predictors and the risk of IE was assessed using binary multivariate logistic regression, including variables selected from the exploratory univariate analysis. Final variables in the model were selected using a backward stepwise approach based on Alkaike information criterion [16] and clinical judgment. This logistic regression model was validated by 2 runs of 2000 bootstrap replications [17] with IE prevalence values of 50% (as in the case-control group) and 4.3% (as in the prospective cohort). After validation, we developed a quantitative score for the risk of endocarditis by rounding the estimated odds ratio (OR) values of the model. This synthetic univariate prediction score was tested in a second logistic regression model and again validated by 2 bootstrap runs, as described above. Additionally, the logistic regression model was calibrated by plotting predicted vs observed probabilities. Finally, bootstrap-based 95% CIs were obtained for sensitivity and specificity and overlaid on the receiver operating characteristic (ROC) plot [18, 19] . A conservative cutoff for the predictive score was based on the maximization of sensitivity, as recommended for screening methods. Data were analyzed using SPSS, version 18.0 (SPSS Inc., Chicago, Illinois) and R [20] .
RESULTS

Incidence of Enterococcal Endocarditis
During the study period (2003-2012), we detected 1515 episodes of E-BSI. The annual distribution is shown in Table 1 . Of these, 679 (2.1 episodes/1000 admissions) occurred in period A (2003) (2004) (2005) (2006) (2007) and 836 (3.1 episodes/1000 admissions) in period B (2008) (2009) (2010) (2011) (2012) . This increase was statistically significant (P < .001). The annual increase in E-BSI was 0.167 episodes/ 1000 admissions (95% CI, .100-.234; P < .001) see Supplementary Data. Overall, 388 patients underwent TEE after the episode of E-BSI: 100 during period A (14.7% of all E-BSI) and 288 during period B (34.4% of all E-BSI).
Enterococcal IE was detected in 65 patients, who accounted for 4.29% of all patients with E-BSI (3.76% in period A and 4.54% in period B). The increase in the annual incidence of enterococcal IE was 0.012 episodes/1000 admissions (95% CI, .004-.020; P = .004). IE was diagnosed in 16.7% of patients who underwent TTE and 35.5% of the patients who underwent TEE. Of all the episodes of enterococcal IE, only 18 cases (27.7%) were detected by TTE; the remaining 47 (72.3%) were demonstrated only after TEE. Sensitivity of TTE and TEE for the diagnosis of enterococcal IE was 32% vs 95% (P < .01).
Comparison of E-BSI Patients With and Without Endocarditis
In order to identify characteristics that could help to identify IE among patients with E-BSI, the 65 cases were compared with the 65 controls. The epidemiological, microbiological, and clinical characteristics of both groups are shown in Table 2 . No differences were detected in age or sex, but patients with IE more frequently presented with a history of stroke (27.7% vs 13.8%, P = .05), immunosuppressive therapy (24.2% vs 10.8%, P = .03), previous heart valve disease (63.0% vs 29.2%, P < .01), and previous heart valve surgery (44.6% vs 24.6%, P = .03). Malignancy, however, was more frequent in controls (23% vs 41.5%, P = .02).
Episodes of IE were caused mainly by Enterococcus faecalis (86.2% vs 58.5%, P < .01). In addition, they were associated with continuous bacteremia (93.8% vs 69.2%, P < .01), community acquisition (43.1% vs 20%, P < .01), and unknown source of infection (38.4% vs 10.7%, P < .01). In the control group, however, E-BSI was mainly nosocomial (69.2% vs 46.2%, P = .01) and had a gastrointestinal origin (48.4% vs 13.8%, P < .01). As for outcome, patients with IE presented more complications (Table 3 ) and had significantly higher mortality (38.4% vs 15.4%, P < .01).
Score for Identifying Bacteremic Patients With a Low Risk of IE
The multivariate analysis showed that enterococcal IE is 9-fold more probable in patients with positive blood cultures in all of 3 blood cultures or the majority of more than 3 blood cultures (OR, 9.9; 95% CI, 2.2-40.6). Other factors independently associated with enterococcal IE were a history of heart valve disease (OR, 3.7; 95% CI, 1.6-8.7) and an unknown source of bacteremia (OR, 7.7; 95% CI, 2.5-23.8). We developed a score using the variables selected in the multivariate model by including those that improved sensitivity and specificity for predicting enterococcal IE (Table 4) . This model validated both very well using bootstrap resampling based on prevalence values of 50% (slope shrinkage factor for the agreement between the training and test samples, 0.88; maximum absolute error in predicted probability, 0.03) and 4.3% (slope shrinkage factor = 0.90; maximum error = 0.02). The ORs of these models were used to obtain representative weights by rounding to develop a synthetic score on a scale of 0 to 12 for the risk of IE in patients with E-BSI. The score, which we called the NOVA score, was based on the following variables: number of positive blood cultures (N) suggestive of continuous bacteremia (3/3 blood cultures or the majority if more than 3), 5 points; unknown origin of bacteremia (O), 4 points; prior valve disease (V), 2 points; and auscultation of a heart murmur (A), 1 point (Table 4 ). The area under the ROC curve for the NOVA score was 0.829 (95% CI, .758-.901). Again, this model was accurately validated by bootstrapping (slope shrinkage factor = 0.99 and 1; maximum error = 0.003 and 0.002, for the resampling runs each stratified by the IE prevalence values of 50% and 4.3%, respectively). The best binary cutoff value for ruling out IE without the need for TEE was established at a NOVA score < 4 points (Figure 1 ). Using this cutoff, the model calibration curve excluded the risk of false negatives (Figure 2 ). The probability of enterococcal None of the 65 patients with enterococcal IE had a NOVA score <4 points in our series (Figure 3) . According to this model, the percentage of patients with E-BSI who would not require echocardiography (score < 4 points) ranged from 14.6% in a setting with a prevalence of endocarditis of 50%, such as our case-control study, to 27.7% in a setting with a 5% prevalence of endocarditis. Therefore, according to our model, in populations with a low prevalence (5%) and high prevalence (20%) of IE, the Notice that a false-negative diagnosis (actual probability > predicted probability) is not expected for a Number of positive blood cultures, Origin of the bacteremia, previous Valve disease, Auscultation of heart murmur (NOVA) score < 4 points.
proportion of patients with E-BSI in whom TEE may not be necessary is 27.7% and 23.4%, respectively (Figure 4 ).
Analysis of a Sample of E-BSI Patients Who Did Not Undergo Echocardiography
After a careful record review, only 3/176 patients (1.70%) without TEE could have had IE according to the selected clinical criteria. All 3 had been treated for at least 4 weeks. Regarding length of treatment with appropriate regimens, only 12/176 patients received more than 2 weeks of therapy (3 with bacteremia of unknown origin, 6 with cholangitis, 1 with osteomyelitis, 1 with infected knee prosthesis, and 1 with fecal peritonitis). As for occurrence of embolic episodes, only 2 patients presented with clinical, microbiological, and/or radiological evidence of septic embolism: a 79-year-old patient with multiple bilateral pulmonary consolidations who refused to undergo TEE and a 92-year-old man with severe Alzheimer disease and L4-S1 osteomyelitis whose family refused TEE. Both patients had been treated for at least 4 weeks before discharge.
Finally, we classified the 176 patients according to the NOVA score. Overall, 106 had a score < 4 points and were treated for a mean of 14 (standard deviation, 5.2) days. None of them presented clinical, microbiological, or radiological signs of embolism or IE during follow-up. Seventy patients had a NOVA score ≥4 points. Three of these patients were thought to have had IE and 2 presented with an embolic complication, as previously mentioned; all had been treated for more than 2 weeks. We cannot rule out the possibility of endocarditis in patients who died early after E-BSI.
DISCUSSION
The frequency of E-BSI is growing, and a significant percentage of cases are associated with IE. In our institution, enterococcal IE is present in 4.3% of all patients with E-BSI, 16.7% of patients undergoing echocardiography, and 35.5% of those who undergo TEE. We describe a simple, bedside predictive score to identify a subgroup of patients with E-BSI in whom the risk of enterococcal IE is very low and who therefore would not require systematic TEE. Our results confirm that, as indicated in the American guidelines, TEE should be the test of choice when the indication is to detect IE, especially if the pretest probability is high, such as in patients with staphylococcal bacteremia, fungemia, prosthetic heart valve, or intracardiac device [21] . Although systematic performance of TEE is not recommended in patients with enterococcal bacteremia in current guidelines, our relatively small percentage of patients with enterococcal bacteremia who underwent TEE (25.6%) reflects the real daily practice and, to date, is the only figure in the literature. In our opinion, TEE should also be performed in patients with enterococcal IE and a NOVA score >4 points.
In many institutions, Enterococcus species is the third most common cause of BSI. The main origins are the gastrointestinal tract and catheter-related infections [22] . The need to rule out Figure 3 . Patients with and without enterococcal endocarditis distributed according to the score in our case-control study (50% endocarditis and 50% no endocarditis). The score was as follows: heart murmur, 1 point; prior valve disease, 2 points; unknown source of bacteremia, 4 points; and continuous bacteremia, 5 points. Abbreviation: NOVA, Number of positive blood cultures, Origin of the bacteremia, previous Valve disease, Auscultation of heart murmur. IE in patients with staphylococcal bacteremia remains open to debate [23] , although some authors suggest that it may be unnecessary in 26%-28% of patients who fulfill specific criteria of uncomplicated BSI [24, 25] . The indication for echocardiography is even less clear in episodes of bacteremia caused by Streptococcus, Candida, and Enterococcus species [26] . Current guidelines for the diagnosis of IE [26] include echocardiography as a key test for the diagnosis and management of patients with IE; however, whether TTE or TEE should be performed first depends on the interpretation of a series of complex clinical, microbiological, and radiological findings. Although the detection rate for TTE is approximately 50% [10] , the efficiency of the technique is affected by factors such as image quality, presence of previous valve disease or prosthetic material, skill of the examiner, and pretest probability of endocarditis. It has been proposed that for patients with a high probability of endocarditis, performance of TEE provides the highest quality-adjusted survival [23] . Our study suggests that most patients with E-BSI (those with a score ≥4 points) should undergo TEE (16.7% positive). We also show that TTE misses more than 70% of episodes of IE and that those patients should undergo TEE.
Our risk prediction score (NOVA) provides physicians with an easy-to-use system that could rapidly determine which patients with E-BSI may require further studies to detect IE. This is done by examining the number of positive blood cultures, the origin of the bacteremia, previous history of valve disease, and auscultation of a heart murmur.
Our study is subject to a series of limitations. First, as it was performed in a single center, and the sample size was not as large as it might have been. Nevertheless, it is the largest sample reported to date and was collected over a long period. Second, since an infectious diseases specialist previously evaluated patients with bacteremia, selection bias should be taken into consideration. Interestingly, despite the intervention of the infectious diseases department, the rate of compliance with echocardiography recommendations remains low (34.4%), and a significant number of patients (1127) with enterococcal bacteremia did not undergo TEE, thus limiting the ability of the study to estimate the real prevalence of IE. However, a further analysis of this population showed that only a very small proportion of patients (1.7%) could have had IE and that even without TEE, they were treated for at least 4 weeks. Finally, ours is a casecontrol study, and the results should be validated in a second cohort and/or prospective study.
Overall, the NOVA score is particularly useful for identifying a subgroup of patients with enterococcal bacteremia who may not need to undergo TEE (sensitivity 100%) because of an extremely low risk of endocarditis. We do not aim to put forward a hypothesis on the treatment of bacteremia or endocarditis. However, we do believe that treatment should be established according to guidelines, predisposing conditions, or clinical presentation (eg, stroke and embolic phenomena) independently of the NOVA score.
In conclusion, our study shows that the prevalence of enterococcal IE depends on whether the sample comprised all cases among those with E-BSI (4.3%), only patients undergoing echocardiography (16.7%), or only patients undergoing TEE (35.5%). Use of TEE in all patients with E-BSI is difficult, costly, time consuming, and subject to complications. Depending on the local prevalence of endocarditis, application of the NOVA bedside prediction score could safely obviate echocardiography in 14%-27% of patients with enterococcal bacteremia.
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